Fixed cutaneous sporotrichosis incognito;Esporotricosis cutánea fija incógnita

Revista Iberoamericana de Micologia

Volumn 21, Issue 3, 2004, Pages 150-152

  Méndez Tovar, Luis Javier ^a,e   Anides Fonseca, Adriana E ^b   Peña González, Gonzálo ^c   Manzano Gayosso, Patricia ^d   López Martínez, Rubén ^d   Hernández Hernández, Francisca ^d   Almeida Arvizu, Victor M ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

^b Hospital de Especialidades3   (Mexico)

^c UNAM ^*  (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^e CSPI Coahuila   (Mexico)

Author keywords

Sporothrix schenckii; Sporotrichosis; Sporotrichosis incognito

Indexed keywords

INDOMETACIN; ITRACONAZOLE; STEROID;

ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; CELLULAR IMMUNITY; CLINICAL FEATURE; ERYTHEMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MEXICO; MYCOLOGY; NONHUMAN; SPOROTHRIX SCHENCKII; SPOROTRICHOSIS; SPOROTRICHOSIS INCOGNITO; STEROID THERAPY;

AGED; ANTIFUNGAL AGENTS; HUMANS; IMMUNOCOMPETENCE; ITRACONAZOLE; MALE; MEXICO; REMISSION INDUCTION; SPOROTHRIX; SPOROTRICHOSIS;

SPOROTHRIX SCHENCKII;

EID: 11244317179     PISSN: 11301406     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. a ed). México DF, Méndez Editores, 2000:185-206.
2. Calderón LE, Ancaya DVL, Mayorga J. Esporotricosis cutánea fija con lesiones satélites. Presentación de un caso. Dermatol Rev Mex 1999; 43: 177-178.
3. Colombo AL, Barchiesi F, McGough DA, Rinaldi MG. Comparison of E test and National Committee for Clinical Laboratory Standars broth macrodilution method for azole antifungal susceptibility testing. J Clin Microbiol 1995; 33: 535-540.
4. Especies con usos no maderables en bosques tropicales y subtropicales en los Estados de Durango, Chihuahua, Jalisco, Michoacán, Guerrero y Oaxaca. www.semarnat.gob.mx/pfnm3/fichas/jatropha_dioica.htm
5. Ghodsi SZ, Shams S, Naraghi Z, Daneshpazhooh M, Akhyani M, Arad S, Ataii L. Case report. An unusual case of cutaneous sporotrichosis and its response to weekly fluconazole. Mycoses 2000; 43: 75-77.
6. Kauffman CA, Pappas PG, McKinsey DS, Greenfield RA, Perfect JR, Cloud GA, Thomas CJ, Dismukes WE. Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infec Dis 1996; 22: 46-50.
7. Lavalle P, Mariat F. Sporotrichosis. Bull Inst Pasteur 1983; 81: 295-322.
8. a ed). México DF, Trillas, 2004: 67-70.
9. Mayorga J, Tarango VM, Barba-Rubio J. Esporotricosis 100 años después. Dermatol Rev Mex 1999; 43 (Supl): S22-29.
10. Méndez-Tovar LJ, Serrano-Jaén L, Almeida-Arvizu VM. Cefotaxima más amikacina asociadas a inmunomodulación en el tratamiento de actinomicetoma resistente a tratamiento convencional. Gac Med Mex 1999; 135: 517-521.
11. Moriya K, Miura NN, Adachi Y, Ohno N. Systemic inflammatory response associated with augmentation and activation of leucocytes in Candida/indomethacin administered mice. Biol Pharm Bull 2002; 25: 816-822.
12. a ed). Baltimore, Williams and Wilkins, 1995:461-523.
13. Soares AMVC, Calvi SA, Peraçoli TS, Fernandez AC, Dias LA, Dos Anjos AR. Modulatory effect of prostaglandins on human monocyte activation for killing of high- and low-virulence strains of Paracoccidioides brasiliensis. Immunology 2001; 102: 480-485.